Defiance ETFs launched its newest leveraged product on Sept. 3, the Defiance Daily Target 2X Short LLY ETF (NASDAQ:LLYZ). The new fund is designed for traders seeking to short pharmaceutical giant Eli Lilly and Co (NYSE:LLY).
The new fund offers investors -200% of Eli Lilly’s daily performance, before fees and expenses, in a straightforward manner, eliminating the need to short the stock or use a margin account. Through the use of derivatives like swaps and options, LLYZ creates single-stock, leveraged inverse access to one of the most closely followed names in healthcare with precision.
